AstraZeneca’s Phase I Study on AZD9592: A Potential Game-Changer in Oncology

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently conducting a Phase I clinical study titled ‘A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of AZD9592, a new drug, either alone or in combination with other anti-cancer agents, in patients with advanced solid tumors.

The study is testing AZD9592 as a monotherapy and in combination with other drugs such as Osimertinib, 5-Fluorouracil, Leucovorin, and Bevacizumab. These interventions are designed to assess the drug’s effectiveness in treating various types of advanced solid tumors, including non-small cell lung cancer and colorectal cancer.

The study follows a non-randomized, parallel intervention model with no masking, focusing primarily on treatment. This design allows researchers to observe the direct effects of AZD9592 and its combinations on the participants.

The study began on December 22, 2022, and is currently recruiting participants. The last update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.

This update from AstraZeneca could positively influence the company’s stock performance and investor sentiment, especially if the results show promising efficacy and safety profiles. The study’s outcomes could also impact the competitive landscape in oncology therapeutics, particularly if AZD9592 proves effective against difficult-to-treat tumors.

The study is ongoing, and further details are available on the ClinicalTrials portal.